Overexpression and amplification of c-myc gene copy number have been reported in ovarian tumours (Dimova et al, 2006), and the inhibition or depletion of PKCα activity has been shown to inhibit drug resistance (Masanek et al, 2002) or sensitise ovarian cancer cells to platinum drugs (Isonishi et al, 2000). This evidence concerns the gene PRKCA and ovarian carcinoma.